Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature
- 13 April 2023
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (7) , 825-831
Abstract
Purpose of Review The study aims to review the literature regarding musculoskeletal complications of aromatase inhibitors and treatment options for these complications. Recent Findings Aromatase inhibitors are common medications to treat hormone receptor-positive breast cancer in postmenopausal women and have been shown to improve survival and prevent disease recurrence. However, 20–60% patients stop treatment prematurely due to side effects. Side effects include joint stiffness and pain, tendonitis, tendon tears, muscle pain, and carpal tunnel syndrome known as aromatase inhibitor musculoskeletal syndrome (AIMSS) as well as bone loss. Proposed mechanisms of AIMSS include decreased estrogen levels, inflammation, and genetic factors. Switching aromatase inhibitors, exercise, non-steroidal anti-inflammatory medications, duloxetine, acupuncture, prednisone, and bisphosphonates are some treatment options for this syndrome and will be discussed in more detail in this review. Summary Aromatase inhibitors are important in the treatment of hormone receptor-positive breast cancer in postmenopausal women. As we study the incidence of side effects of these medications including bone loss and AIMSS and determine the mechanisms of these symptoms and possible treatment options, we will decrease the incidence of patients discontinuing treatment prematurely and improve symptoms, quality of life, and survival in this patient population.Keywords
This publication has 38 references indexed in Scilit:
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerJournal of Clinical Oncology, 2012
- Rheumatoid arthritis and aromatase inhibitorsJoint Bone Spine, 2011
- Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?Breast Cancer Research and Treatment, 2010
- Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) studyBreast Cancer Research and Treatment, 2009
- Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivorsCancer, 2009
- Accelerated Cutaneous Nodulosis Associated with Aromatase Inhibitor Therapy in a Patient with Rheumatoid Arthritis: Figure 1.The Journal of Rheumatology, 2009
- Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230Journal of Clinical Oncology, 2008
- Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial PatientsClinical Breast Cancer, 2007
- Severe disabling tendinopathy caused by anastrazoleRheumatology, 2007
- Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imagingBreast Cancer Research and Treatment, 2006